Lataa...
Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics
New hepatitis B virus (HBV) therapies are expected to have breakthrough benefit for patients. HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalization of serum aminotransferases off therapy. Virologic or complete cure additionally includes loss of HBV c...
Tallennettuna:
| Julkaisussa: | Clin Infect Dis |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5848252/ https://ncbi.nlm.nih.gov/pubmed/28200098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix129 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|